^
Association details:
| Biomarker: | FGFR4 expression |
|---|---|
| Cancer: | Hepatocellular Cancer |
| Drug: | spartalizumab (PDR001) (PD1 inhibitor) + roblitinib (FGF401) (FGFR4 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A first-in-human phase 1/2 study of FGF401 and combination of FGF401 with spartalizumab in patients with hepatocellular carcinoma or biomarker-selected solid tumors
Published date:
06/02/2022
Excerpt:
Twelve patients received FGF401 plus spartalizumab. RP2D was established as FGF401 120 mg qd and spartalizumab 300 mg Q3W; 2 patients reported PR….At biologically active doses, FGF401 alone or combined with spartalizumab was safe in patients with FGFR4/KLB-positive tumors including HCC. Preliminary clinical efficacy was observed.
DOI:
ttps://doi.org/10.1186/s13046-022-02383-5
